Category: 2-Minute Science

The Hidradenitis Suppurutiva Awareness Week is held annually to spread knowledge about the disease and how it affects patients. Affecting roughly 1% of the population, HS causes significant physical and emotional challenges that are often overlooked. The HS awareness week aims to spread knowledge about the disease and how it affects patients.

HS is believed to result from a complex mix of genetic predisposition, lifestyle factors, and immune system dysfunction, driving a continuous cycle of inflammation. It commonly presents as painful nodules, abscesses, draining tunnels beneath the skin, and scarring.

These symptoms often cause physical discomfort and disability, affecting quality of life, personal relationships, and career opportunities.
People living with HS respond differently to treatments, and we believe that raising awareness and supporting research is key to developing tailored treatment strategies that truly address their challenges.

Our dermatology biomarkers enable precision medicine by providing information about ongoing pathological processes, such as damage and repair, within the ECM. This can guide targeted treatments and therapies, enhancing patient outcomes and personalized medicine approaches. At the same time, our markers, supported by our long history of experience and expertise, expedite drug development by specifically identifying target populations and reducing costs, over proteomic providers’ hopes to hit the right target by chance.

If you want to find out more about how our biomarkers can be applied in Hidradenitis Suppurutiva, click on the button below.

April 11th marks World Parkinson’s Day, which aims to spread awareness for the millions of patients with Parkinson’s.

Parkinson’s is the fastest growing neurological disease and there currently is no cure. One of the main challenges in developing effective treatments for Parkinson’s disease is the need to diagnose patients early, identify those with rapid disease progression, and monitor treatment response through reliable indicators.

Nordic Bioscience has developed a blood-based biomarker targeting a pathological fragment of alpha-synuclein cleaved by Calpain-1, which aggregates into fibrils as part of the disease process. This biomarker has been shown to be upregulated in patients with Parkinson’s disease. Since this pathological fragment is generated before fibril aggregation occurs, we can identify patients early.

In our paper published in Scientific Reports, we describe the development and potential of this biomarker in two clinical cohorts of patients with Parkinson’s Disease.

September is pulmonary fibrosis (PF) awareness month—a progressive lung disease that affects over 200,000 people in the United States alone. PF causes scarring of lung tissue, leading to severe breathing difficulties and reduced quality of life.

At Nordic Bioscience, we are dedicated to advancing the development of biomarkers that provide deeper insights into disease progression in pulmonary fibrosis. Together with our collaborators, we contributed to the Lancet publication:
“Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation.”

This research represents a step forward in identifying endotypes that can help improve the monitoring of the disease and guided therapy, ultimately enhancing patient care.

We hope our findings encourage continued research and collaboration, working together to make a lasting impact!